Vetoquinol (VETO) - Total Liabilities
Based on the latest financial reports, Vetoquinol (VETO) has total liabilities worth €158.29 Million EUR (≈ $185.05 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Vetoquinol - Total Liabilities Trend (2004–2024)
This chart illustrates how Vetoquinol's total liabilities have evolved over time, based on quarterly financial data. Explore VETO long-term investment intensity to see how much of total assets are deployed in long-term investments.
Vetoquinol Competitors by Total Liabilities
The table below lists competitors of Vetoquinol ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Miracle Automation Engineering
SHE:002009
|
China | CN¥3.47 Billion |
|
Nanjing Xinlian Electronics Co Ltd
SHE:002546
|
China | CN¥363.62 Million |
|
Changjiang & Jinggong Steel Building Group Co Ltd
SHG:600496
|
China | CN¥17.25 Billion |
|
Foxsemicon Integrated Technology Inc
TW:3413
|
Taiwan | NT$9.49 Billion |
|
Retail Estates - Sicafi
BR:RET
|
Belgium | €903.57 Million |
|
Hunan Er Kang Pharmaceutical
SHE:300267
|
China | CN¥634.44 Million |
|
WAVE LIFE SCIENCES LTD.
F:1U5
|
Germany | €71.81 Million |
|
Top Energy Shanxi Co Ltd
SHG:600780
|
China | CN¥3.64 Billion |
Liability Composition Analysis (2004–2024)
This chart breaks down Vetoquinol's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Vetoquinol asset portfolio.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vetoquinol's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vetoquinol (2004–2024)
The table below shows the annual total liabilities of Vetoquinol from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €168.20 Million ≈ $196.64 Million |
+1.86% |
| 2023-12-31 | €165.12 Million ≈ $193.04 Million |
-1.23% |
| 2022-12-31 | €167.19 Million ≈ $195.46 Million |
-8.75% |
| 2021-12-31 | €183.21 Million ≈ $214.19 Million |
-33.20% |
| 2020-12-31 | €274.26 Million ≈ $320.64 Million |
+118.56% |
| 2019-12-31 | €125.49 Million ≈ $146.71 Million |
+22.43% |
| 2018-12-31 | €102.50 Million ≈ $119.83 Million |
-5.31% |
| 2017-12-31 | €108.24 Million ≈ $126.55 Million |
-11.78% |
| 2016-12-31 | €122.70 Million ≈ $143.45 Million |
-0.23% |
| 2015-12-31 | €122.98 Million ≈ $143.78 Million |
-18.54% |
| 2014-12-31 | €150.97 Million ≈ $176.50 Million |
+30.28% |
| 2013-12-31 | €115.88 Million ≈ $135.47 Million |
-9.77% |
| 2012-12-31 | €128.43 Million ≈ $150.15 Million |
+20.00% |
| 2011-12-31 | €107.02 Million ≈ $125.12 Million |
-14.50% |
| 2010-12-31 | €125.18 Million ≈ $146.34 Million |
-2.75% |
| 2009-12-31 | €128.72 Million ≈ $150.49 Million |
+29.53% |
| 2008-12-31 | €99.38 Million ≈ $116.18 Million |
-1.15% |
| 2007-12-31 | €100.53 Million ≈ $117.53 Million |
+1.06% |
| 2006-12-31 | €99.47 Million ≈ $116.30 Million |
-11.89% |
| 2005-12-31 | €112.90 Million ≈ $131.99 Million |
+6.93% |
| 2004-12-31 | €105.58 Million ≈ $123.44 Million |
-- |
About Vetoquinol
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal … Read more